



ALLIANCE FOR EYE AND VISION RESEARCH (AEVR)

*continues its series of educational briefings on exciting new developments
in eye and vision research and*

Invites you to join us for a first-ever Luncheon Briefing on

Thyroid Eye Disease

**Thursday, November 14, 2019
House Rayburn 2075
12 Noon – 1:15 pm**

Featured Speaker:
Raymond Douglas, MD, PhD
Cedars-Sinai Medical Center, Los Angeles, California

Come experience the world through a Thyroid Eye Disease patient's eyes by
trying on a set of diplopia (double vision) goggles.

Please R.S.V.P. to Dina Beaumont @ 202-407-8325 or dinabeau@aol.com

**AEVR, a 501(c)3 Non-Profit Educational Foundation through its
Decade of Vision 2010-2020 Initiative is pleased to host this widely attended
event featuring an eye-healthy luncheon.**

Thyroid Eye Disease

November 14, 2019, 12:00 Noon – 1:15 pm, House Rayburn 2075

RSVP to: 202-407-8325 or dinabeau@aol.com

What is Thyroid Eye Disease, and Why is it Important?

Thyroid eye disease (TED) is a serious, debilitating, and vision-threatening autoimmune disease where the immune system attacks muscles and other tissue behind and around the eyes. TED has active and inactive phases. Currently, **there is no approved** therapy to treat TED. Current treatment during active TED consists of corticosteroids and ocular lubricants, which only treat the symptoms. As a result, physicians must wait for progression to inactivity and for inflammation to subside to perform complex surgical procedures that may be associated with additional complications, depending on the severity of symptoms.

The National Institutes of Health (NIH) through its National Eye Institute (NEI) is funding research into TED, as is private industry.

Types of TED

- Active TED: TED has a limited window of activity that can last up to three years. Patients suffer inflammation, eye bulging and misalignment, and double vision. In some cases, disease progression may lead to blindness due to optic nerve damage.
- Inactive TED: Inactive TED often progresses to leave patients with irreversible and vision impairing consequences, requiring complex and costly surgical intervention that may never fully restore vision or appearance.

TED and Graves' Disease: While TED is most often seen in patients with Graves' disease – affecting up to half of Graves' patients – it is a distinct disease that requires separate treatment. A diagnosis of TED may even precede a finding of Graves' and can serve as an early warning sign of impending thyroid dysfunction. It also can occur in Hashimoto's hypothyroidism or euthyroid patients.

Living with TED

People living with TED frequently experience long-term functional, psychosocial, and economic burdens, including inability to work and perform activities of daily living.

About the Speaker...

Raymond Douglas, MD, PhD, is a board-certified oculoplastic surgeon in Beverly Hills, California and serves as the Director of the Orbital and Thyroid Eye Disease Program at Cedars-Sinai Medical Center in Los Angeles, California. Patients from around the country with thyroid eye disease, previous unsuccessful eyelid surgery (blepharoplasty), cancers of the eyelids and face, and trauma-induced injuries all seek his expert care. In his presentation, Dr. Douglas will focus on his research and clinical trials for treatments of TED.

**AEVR is pleased to host this widely attended event
featuring an Eye-Healthy luncheon.**